GelSana

GelSana Therapeutics is a biomaterials company based in Aurora, Colorado, founded in 2020. The company focuses on developing innovative hydrogel-based products for wound healing, particularly targeting chronic wounds such as diabetic ulcers. Led by founder and CEO Melissa Krebs, GelSana operates within the $78 billion wound care market, addressing significant healthcare challenges associated with wounds that do not heal effectively.

The company's core technology features a unique polymer-based hydrogel system that reduces inflammation, manages moisture, and enables sustained drug delivery to promote healing. GelSana's first commercial product, Cleragel, is designed to combat infection and inflammation without the use of drugs. The company is also working on additional wound dressing products aimed at enhancing tissue regeneration and antimicrobial applications. GelSana's advancements aim to improve healing rates and reduce the risks of infection and amputation associated with chronic wounds.